Login / Signup

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Philip D HomeRoopa MehtaKhadija A S HafidhOlesya Y GurovaAgustina AlvarezPaul SerafiniMir-Masoud Pourrahmat
Published in: Diabetes, obesity & metabolism (2021)
iGlarLixi appears to offer clinical benefit in glucose control and bodyweight change in people needing both basal and meal-time intervention.
Keyphrases
  • randomized controlled trial
  • type diabetes
  • blood pressure
  • adipose tissue
  • metabolic syndrome
  • skeletal muscle
  • insulin resistance
  • smoking cessation
  • clinical evaluation